(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.72%.
Adagene's earnings in 2026 is -$17,609,413.On average, 9 Wall Street analysts forecast ADAG's earnings for 2026 to be -$25,493,450, with the lowest ADAG earnings forecast at -$41,213,621, and the highest ADAG earnings forecast at -$9,950,975. On average, 8 Wall Street analysts forecast ADAG's earnings for 2027 to be -$24,468,736, with the lowest ADAG earnings forecast at -$30,184,624, and the highest ADAG earnings forecast at -$11,194,847.
In 2028, ADAG is forecast to generate -$30,960,563 in earnings, with the lowest earnings forecast at -$42,955,041 and the highest earnings forecast at -$14,304,526.